Condition overview
Ibogaine for depression
Depression care already includes established pathways — psychotherapy, medications, interventional psychiatry, and more. People sometimes ask whether IV ibogaine infusion might help mood symptoms. Evidence for mood benefit is limited; much public conversation extrapolates from addiction studies or oral-route observational work. Ibogaine is not FDA-approved for depression.
Programs discussed on this site for physician-supervised IV ibogaine infusion are provisionally available in Mexico — not an FDA-approved U.S. clinic treatment. Educational only; not legal advice.
Keep established care in the frame
If you are living with depression, continuity with qualified clinicians comes first. Exploring ibogaine as an educational topic should not interrupt medications abruptly or replace urgent mental-health care. Active suicidal crisis requires emergency and psychiatric pathways — not an inquiry form.
What we can responsibly say
- There is research interest in ibogaine/noribogaine and mood-related outcomes
- Some observational contexts (including veteran cohorts with PTSD/depression symptom measures) report open-label changes — often after oral ibogaine protocols
- Cardiac risk (QTc) is a central safety theme across exposure routes
- This site’s entity is IV psychoactive infusion under physician supervision, with honest labeling that IV controlled evidence is sparse
Cannot say: FDA-approved antidepressant; guaranteed remission; “proven by Nature Medicine as IV therapy” (Cherian 2024 is oral ibogaine + IV magnesium, open-label); equivalent evidence maturity to ketamine clinic protocols.
IV ibogaine vs ketamine for depression
| Axis | Ketamine / esketamine | IV ibogaine infusion |
|---|---|---|
| Evidence maturity | More clinical infrastructure | Limited; sparse IV controlled data |
| U.S. regulatory posture | Approved anesthetic; esketamine labeled pathway | Schedule I; not FDA-approved |
| Dominant risk narrative | Dissociation, BP/HR, rare psych AEs | QTc / arrhythmia + prolonged intensity |
Deep dive: ibogaine vs ketamine.
How the infusion journey relates to depression care
- Psychiatric history and current regimen review (including QT-prolonging agents)
- Medical/cardiac clearance
- Physician-supervised IV ibogaine infusion with telemetry
- Observation through the acute window
- Integration: therapy continuity, medication plan, safety planning
Overlap with PTSD narratives
Depression searches often co-travel with PTSD and veteran TBI discussions. Open-label magnesium–ibogaine work in special operations veterans measured multiple symptom domains after oral ibogaine with IV magnesium. That paper is research landscape — not proof that IV psychoactive ibogaine is an approved depression treatment. See ibogaine for PTSD.
Psychiatric and medical caution
- Medication washout or changes must be clinician-directed
- Cardiac screening remains relevant regardless of psychiatric motivation
- Integration support matters when intense experiences intersect with mood disorders
- Expectancy and temporary afterglow are not the same as durable remission
Continue with safety & screening, what infusion means, and confidential inquiry.
Next step
Ask about mood-related screening questions
Screening comes before any treatment conversation — not after a sales pitch. Supervised IV ibogaine infusion inquiry is available provisionally in Mexico; not a U.S. FDA-approved clinic.